ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study
British Journal of Dermatology
◽
10.1111/bjd.19460
◽
2020
◽
Cited By ~ 1
Author(s):
M.J. Cork
◽
D. Thaçi
◽
L.F. Eichenfield
◽
P.D. Arkwright
◽
X. Sun
◽
...
Keyword(s):
Atopic Dermatitis
◽
Phase Iii
◽
Extension Study
◽
Severe Atopic Dermatitis
◽
Open Label
◽
Safety And Efficacy
◽
Open Label Extension
◽
Open Label Phase
◽
Subsequent Phase
Download Full-text
Related Documents
Cited By
References
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Journal of the American Academy of Dermatology
◽
10.1016/j.jaad.2019.07.074
◽
2020
◽
Vol 82
(2)
◽
pp. 377-388
◽
Cited By ~ 31
Author(s):
Mette Deleuran
◽
Diamant Thaçi
◽
Lisa A. Beck
◽
Marjolein de Bruin-Weller
◽
Andrew Blauvelt
◽
...
Keyword(s):
Atopic Dermatitis
◽
Extension Study
◽
Severe Atopic Dermatitis
◽
Open Label
◽
Phase 3
◽
Safety And Efficacy
◽
Open Label Extension
Download Full-text
Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension
British Journal of Dermatology
◽
10.1111/bjd.18476
◽
2019
◽
Vol 182
(1)
◽
pp. 85-96
◽
Cited By ~ 22
Author(s):
M.J. Cork
◽
D. Thaçi
◽
L.F. Eichenfield
◽
P.D. Arkwright
◽
T. Hultsch
◽
...
Keyword(s):
Atopic Dermatitis
◽
Phase Ii
◽
Phase Iii
◽
Severe Atopic Dermatitis
◽
Open Label
◽
Open Label Extension
◽
Subsequent Phase
◽
Open Label Trial
Download Full-text
103. Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study
Rheumatology
◽
10.1093/rheumatology/keu101.024
◽
2014
◽
Vol 53
(suppl_1)
◽
pp. i96-i96
◽
Cited By ~ 1
Author(s):
Edward Keystone
◽
Robert Landewé
◽
Ronald van Vollenhoven
◽
Bernard Combe
◽
Vibeke Strand
◽
...
Keyword(s):
Rheumatoid Arthritis
◽
Randomized Controlled Trial
◽
Controlled Trial
◽
Certolizumab Pegol
◽
Extension Study
◽
Open Label
◽
Safety And Efficacy
◽
Randomized Controlled
◽
Open Label Extension
Download Full-text
P036 LONG-TERM SAFETY AND EFFICACY OF THE ANTI-MUCOSAL ADDRESSIN CELL ADHESION MOLECULE-1 (MADCAM-1) ANTIBODY SHP647 IN ULCERATIVE COLITIS: AN OPEN-LABEL EXTENSION STUDY (TURANDOT II)
Gastroenterology
◽
10.1053/j.gastro.2019.01.088
◽
2019
◽
Vol 156
(3)
◽
pp. S25-S26
Author(s):
Walter Reinisch
◽
William J. Sandborn
◽
Silvio Danese
◽
Xavier Hébuterne
◽
Bruce Salzberg
◽
...
Keyword(s):
Ulcerative Colitis
◽
Cell Adhesion
◽
Adhesion Molecule
◽
Cell Adhesion Molecule
◽
Extension Study
◽
Open Label
◽
Safety And Efficacy
◽
Open Label Extension
◽
Cell Adhesion Molecule 1
Download Full-text
Long-term treatment of Cushing’s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial
Endocrine
◽
10.1007/s12020-017-1316-3
◽
2017
◽
Vol 57
(1)
◽
pp. 156-165
◽
Cited By ~ 20
Author(s):
S. Petersenn
◽
L. R. Salgado
◽
J. Schopohl
◽
L. Portocarrero-Ortiz
◽
G. Arnaldi
◽
...
Keyword(s):
Cushing’S Disease
◽
Term Treatment
◽
Phase Iii
◽
Cushing's Disease
◽
Extension Study
◽
Open Label
◽
Phase Iii Trial
◽
Long Term Treatment
◽
Open Label Extension
Download Full-text
Long-term safety and efficacy of lumacaftor–ivacaftor therapy in children aged 6–11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study
The Lancet Respiratory Medicine
◽
10.1016/s2213-2600(20)30517-8
◽
2021
◽
Author(s):
Mark A Chilvers
◽
Jane C Davies
◽
Carlos Milla
◽
Simon Tian
◽
Zifei Han
◽
...
Keyword(s):
Cystic Fibrosis
◽
Extension Study
◽
Open Label
◽
Phase 3
◽
Safety And Efficacy
◽
Open Label Extension
Download Full-text
MP31-01 LONG-TERM SAFETY AND EFFICACY OF SER120 1.5 MCG IN PATIENTS WITH NOCTURIA: RESULTS FROM A 2-YEAR OPEN-LABEL EXTENSION STUDY
The Journal of Urology
◽
10.1016/j.juro.2017.02.955
◽
2017
◽
Vol 197
(4S)
◽
Author(s):
Scott MacDiarmid
◽
J.P. Nicandro
◽
Maria Cheng
◽
Steven Abrams
◽
Seymour Fein
◽
...
Keyword(s):
Extension Study
◽
Open Label
◽
Safety And Efficacy
◽
Open Label Extension
Download Full-text
Long-Term Safety and Efficacy of a Once-Daily Formulation of Alfuzosin 10 mg in Patients with Symptomatic Benign Prostatic Hyperplasia: Open-Label Extension Study
European Urology
◽
10.1016/s0302-2838(01)00016-1
◽
2002
◽
Vol 41
(1)
◽
pp. 54-61
◽
Cited By ~ 43
Author(s):
P van Kerrebroeck
◽
A Jardin
◽
P van Cangh
◽
K.U Laval
Keyword(s):
Benign Prostatic Hyperplasia
◽
Prostatic Hyperplasia
◽
Extension Study
◽
Open Label
◽
Symptomatic Benign Prostatic Hyperplasia
◽
Once Daily
◽
Safety And Efficacy
◽
Open Label Extension
Download Full-text
Abobotulinumtoxin A in children with lower limb spasticity due to cerebral palsy: Safety and efficacy results of a Phase III open-label extension study
Gait & Posture
◽
10.1016/j.gaitpost.2016.07.275
◽
2016
◽
Vol 49
◽
pp. 222
Keyword(s):
Cerebral Palsy
◽
Lower Limb
◽
Phase Iii
◽
Extension Study
◽
Open Label
◽
Safety And Efficacy
◽
Open Label Extension
◽
Limb Spasticity
◽
Lower Limb Spasticity
Download Full-text
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
The Lancet Respiratory Medicine
◽
10.1016/s2213-2600(21)00322-2
◽
2021
◽
Author(s):
Michael E Wechsler
◽
Linda B Ford
◽
Jorge F Maspero
◽
Ian D Pavord
◽
Alberto Papi
◽
...
Keyword(s):
Severe Asthma
◽
Extension Study
◽
Open Label
◽
Safety And Efficacy
◽
Open Label Extension
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close